Barbara Slusher is an Associate Professor of Neurology and Psychiatry and the Director of the Brain Science Institute (BSI) NeuroTranslational Drug Discovery Program.
Before joining Johns Hopkins in September 2009, Dr. Slusher spent 18 years in the pharmaceutical industry holding positions at companies including ICI Pharmaceuticals, Zeneca (now Astra-Zeneca), Guilford Pharmaceuticals, MGI Pharma, and the Eisai Research Institute, with several years at the level of Senior Vice President of Research and Translational Development.
She has extensive experience in drug discovery through Phase I/IIa clinical development and has participated in multiple FDA meetings and both IND and NDA regulatory filings. She has also been involved in the successful development, launch and postmarketing support of four currently marketed medicines.
At Johns Hopkins, Dr. Slusher leads the largest integrated drug discovery program on campus, responsible for translating basic science discoveries at Hopkins into new drug therapies for neurological and psychiatric disorders. Dr. Slusher is a member of the JHU NIMH Center for Novel Therapeutics of HIV-associated Cognitive Disorders, and serves as the Director for the Therapeutics Development Core. Dr. Slusher has published over 120 scientific articles and is the inventor on over 50 issued patents. She is a co-founder of Cerecor, a new biotechnology company which will commercialize Johns Hopkins drug discovery interventions, and is leading the National Consortium for Academic Drug Discovery scientists.
Dr. Slusher received her Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine and a Master’s degree in Management from the Johns Hopkins Carey School of Business. Dr. Slusher’s extensive track record in drug development, as well as her strong ties to Industry, make her an exceptional leader for the Drugs/Biologics/Vaccines/Devices Translational Research Community.